PriceTargets.com logo

Inhibrx - INBX Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $36.50
  • Forecasted Upside: 62.95%
  • Number of Analysts: 3
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 3 Buy Ratings
  • 0 Strong Buy Ratings
$22.40 As of 12/5/2023 11:09 AM ET
▼ -0.34 (-1.50%)

This chart shows the closing price for INBX by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Inhibrx Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for INBX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for INBX

Analyst Price Target is $36.50
▲ +62.95% Upside Potential
This price target is based on 3 analysts offering 12 month price targets for Inhibrx in the last 3 months. The average price target is $36.50, with a high forecast of $46.00 and a low forecast of $27.00. The average price target represents a 62.95% upside from the last price of $22.40.

This chart shows the closing price for INBX for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 3 investment analysts is to buy stock in Inhibrx. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/12/2022
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/10/2022
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/9/2022
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/9/2023
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/7/2023
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/5/2023
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/4/2023
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/4/2023

Latest Recommendations

  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
11/20/2023JMP SecuritiesReiterated RatingMarket Outperform ➝ Market Outperform$27.00Low
8/23/2023JMP SecuritiesLower TargetOutperform ➝ Outperform$35.00 ➝ $27.00Low
8/8/2023Lifesci CapitalReiterated RatingOutperformLow
4/26/2023Lifesci CapitalReiterated RatingOutperformLow
3/8/2023JMP SecuritiesLower TargetMarket Outperform$40.00 ➝ $35.00Low
3/7/2023Credit Suisse GroupReiterated RatingOutperform$46.00Low
11/8/2022Credit Suisse GroupLower TargetOutperform$48.00 ➝ $46.00Low
10/5/2022JMP SecuritiesReiterated RatingBuy$40.00Low
10/5/2022Evercore ISIBoost TargetOutperform$54.00 ➝ $60.00Low
8/15/2022Credit Suisse GroupLower Target$48.00N/A
8/9/2022Credit Suisse GroupLower TargetOutperform$53.00 ➝ $48.00Low
7/6/2022JMP SecuritiesReiterated RatingBuy$40.00N/A
6/6/2022JMP SecuritiesReiterated RatingBuy$40.00Low
4/11/2022JMP SecuritiesReiterated RatingBuy$40.00Medium
3/16/2022Sumitomo Mitsui Financial GroupInitiated CoverageOutperform$40.00High
3/2/2022JMP SecuritiesLower TargetMarket Outperform$53.00 ➝ $40.00Low
1/5/2022JMP SecuritiesReiterated RatingBuy$53.00High
11/10/2021Credit Suisse GroupBoost TargetOutperform$44.00 ➝ $53.00Low
11/2/2021JMP SecuritiesBoost TargetOutperform$46.00 ➝ $53.00Low
10/13/2021JMP SecuritiesReiterated RatingBuy$46.00High
9/21/2021JMP SecuritiesInitiated CoverageBuy$46.00High
4/26/2021Credit Suisse GroupInitiated CoverageOutperform$44.00High
2/3/2021Credit Suisse GroupBoost Target$28.00 ➝ $44.00Low
10/15/2020Lifesci CapitalReiterated RatingOutperformMedium
9/14/2020Jefferies Financial GroupInitiated CoverageBuy$30.00High
9/14/2020Evercore ISIInitiated CoverageOutperform$30.00High
9/14/2020Credit Suisse GroupInitiated CoverageOutperform$26.00High
(Data available from 12/5/2018 forward)

News Sentiment Rating

0.41 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 3 very positive mentions
  • 2 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
Mentions as of
5/8/2023
  • 4 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
6/7/2023
  • 1 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
7/7/2023
  • 1 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/6/2023
  • 7 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/5/2023
  • 2 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/5/2023
  • 1 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/4/2023
  • 1 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/4/2023

Current Sentiment

  • 1 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

Inhibrx logo
Inhibrx, Inc., a clinical-stage biopharmaceutical company, focuses on developing a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidates include INBRX-109, a tetravalent agonist of death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, and pancreatic adenocarcinoma; INBRX-105, a tetravalent conditional agonist of programmed death-ligand 1 and a conditional agonist of 4-1BB that is in Phase 1 clinical trials to treat patients with locally advanced or metastatic solid tumors; and INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency. It also develops INBRX-106, a hexavalent agonist of OX40 for a range of oncology indications. The company has collaboration with 2seventy bio, Inc., Bristol-Myers Squibb Company, and Chiesi Farmaceutici S.p.A. The company was founded in 2010 and is headquartered in La Jolla, California.
Read More

Today's Range

Now: $22.40
Low: $21.54
High: $22.54

50 Day Range

MA: $18.54
Low: $14.50
High: $22.74

52 Week Range

Now: $22.40
Low: $14.31
High: $30.71

Volume

13,310 shs

Average Volume

398,653 shs

Market Capitalization

$1.06 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.8

Frequently Asked Questions

What sell-side analysts currently cover shares of Inhibrx?

The following Wall Street research analysts have issued reports on Inhibrx in the last twelve months: Credit Suisse Group AG, JMP Securities, and Lifesci Capital.
View the latest analyst ratings for INBX.

What is the current price target for Inhibrx?

2 Wall Street analysts have set twelve-month price targets for Inhibrx in the last year. Their average twelve-month price target is $36.50, suggesting a possible upside of 60.5%. Credit Suisse Group AG has the highest price target set, predicting INBX will reach $46.00 in the next twelve months. JMP Securities has the lowest price target set, forecasting a price of $27.00 for Inhibrx in the next year.
View the latest price targets for INBX.

What is the current consensus analyst rating for Inhibrx?

Inhibrx currently has 3 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe INBX will outperform the market and that investors should add to their positions of Inhibrx.
View the latest ratings for INBX.

What other companies compete with Inhibrx?

Other companies that are similar to Inhibrx include Relay Therapeutics, BioCryst Pharmaceuticals, Editas Medicine, Apogee Therapeutics and Kymera Therapeutics. Learn More about companies similar to Inhibrx.

How do I contact Inhibrx's investor relations team?

Inhibrx's physical mailing address is 11025 N. TORREY PINES ROAD SUITE 200, LA JOLLA CA, 92037. The company's listed phone number is 858-795-4220 and its investor relations email address is [email protected]. The official website for Inhibrx is www.inhibrx.com. Learn More about contacing Inhibrx investor relations.